We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effects of nucleoside analogue prescription for hepatitis B on the incidence of liver cancer in Hong Kong: a territory-wide ecological study.
- Authors
Seto, W.‐K.; Lau, E. H. Y.; Wu, J. T. K.; Hung, I. F. N.; Leung, W. K.; Cheung, K.‐S.; Fung, J.; Lai, C.‐L.; Yuen, M.‐F.
- Abstract
Background The temporal relationship between nucleoside analogue therapy for chronic hepatitis B ( CHB) and liver cancer development has not been evaluated at a population level. Aim To investigate the impact of nucleoside analogue prescription on liver cancer incidence in a CHB-prevalent region. Methods We obtained territory-wide nucleoside analogue prescription data from 1999, when nucleoside analogue was first available in Hong Kong, to 2012 and the population-based liver cancer incidence data from 1990 to 2012. We compared the liver cancer incidences from 1990 to 1998 and 1999 to 2012 with adjustment for local hepatitis B surface antigen seroprevalence. Results Nucleoside analogue prescription patient headcount increased from 2006 per year in 1999 to 26 411 in 2012. Prescription volume in 2012 was highest among 55-64 years (30.3%), higher than 65-74 years (13.0%) and ≥75 years (5.8%). Age-standardised liver cancer incidence 1999-2012 decreased by 1.88%/year (95% CI 3.34% to 0.42%/year). NA therapy was associated with decline in age-adjusted liver cancer incidence (2.7 per 100 000 persons, P < 0.001, 95% CI 1.4-4.0 per 100 000 persons). Fifty-five to sixty-four years age group had the most significant decline (men: 24.0 per 100 000 persons, P = 0.001, 95% CI 11.4-36.6 per 100 000 persons; women: 8.5 per 100 000 persons, P = 0.009, 95% CI 2.3-14.6 per 100 000 persons). No significant association was noted in age groups 65-74 years and ≥75 years (both P > 0.05). Conclusions Nucleoside analogue prescription was associated with a reduction of overall liver cancer incidence in a CHB-prevalent region. The lack of association among individuals of ≥65 years was consistent with the low nucleoside analogue prescription volume in elderly patients, mitigating the impact of CHB treatment on liver cancer.
- Subjects
LIVER cancer; NUCLEOSIDES; CHRONIC hepatitis B; CANCER prevention; CANCER treatment; THERAPEUTICS
- Publication
Alimentary Pharmacology & Therapeutics, 2017, Vol 45, Issue 4, p501
- ISSN
0269-2813
- Publication type
Article
- DOI
10.1111/apt.13895